The NeuroBell team have been developing the science and technology underpinning the company since 2015. CEO Dr. Mark O’Sullivan and CSO Dr. Alison O’Shea completed their PhD and Postdoctoral Research at the internationally-renowned INFANT Research Centre at University College Cork, Ireland, where they focused on developing novel technologies to improve the accuracy and availability of neonatal brain monitoring systems.

​

Supported by an Enterprise Ireland Commercialisation Fund in 2021, CTO Colm Murphy joined, bringing a wealth of development experience from the electronics and medical device industries. NeuroBell was founded as a UCC spinout in 2023 to commercialise the technology including patent-pending IP, deep learning AI, and clinically-annotated EEG databases.

​

NeuroBell secured in €2.1 million in Seed Funding in 2023 led by Furthr VC, Atlantic Bridge, HBAN Medtech Syndicate, and Enterprise Ireland. NeuroBell has built a team of exceptional scientists and engineers to bring their technology to the hands of medical teams globally to help the most vulnerable of patient populations.